Person
Dr. Yvonne Linney
Chief Operating Officer of Artificial Inc., a lab automation company providing a first-of-its-kind orchestration platform for life science labs. Joined Artificial in January 2021, bringing 30+ years of executive experience at industry-leading life sciences and diagnostic companies. Previously COO and then CEO of Transcriptic (now Strateos), where she brokered a multi-year, multi-million dollar agreement with Eli Lilly.
Before that, VP and GM of the Life Science Solutions Division at Agilent Technologies, where she established a $1.5B Life Science Group. Also held senior roles at Bayer Diagnostics (now Siemens Healthcare), Caliper Life Sciences, and Amersham International (now GE Healthcare). Serves on the board of Bionano Genomics. Holds a BS in Microbiology and Virology from Warwick University and a PhD in Genetics from Leicester University, UK.
British · 1 current role
Physical AI footprint (1)
The physical AI companies Dr. is connected to that DEPLOY verifies. The full record is one click away.
- COO
Artificial Inc.
Current roles (1)
- Artificial COO
Sources (3)
- https://www.businesswire.com/news/home/20210119005125/en/Artificial-Inc.-Expands-Leadership-Team-and-Board-of-Directors-to-Catalyze-the-Labs-Digital-Revolution
- https://ir.bionanogenomics.com/static-files/e7088a54-dafe-4471-8cb0-e6d557089e99
- https://www.citybiz.co/article/365730/sengenics-appoints-yvonne-linney-phd-as-board-director/
Deploy Watch
Track Dr. Yvonne Linney on Deploy.
We notify you when a verified role changes, a founded-company event lands, or litigation surfaces.